Genome Editing Approved: FDA fast-tracks first human embryo editing technology by May 15

41%

probability · 41% confidence · 16 days

US startups actively exploring genome editing in human embryos with ethical concerns raised. Signal shows regulatory momentum and biotech push; FDA has shown willingness to fast-track novel gene therapies. However, embryo editing remains extraordinarily controversial and regulatory bar is extremely high. Base rate for tech regulatory approval (90 days) is 25%; embryo editing is far more restrictive. This is ambitious but signals suggest some pathway forward.

Brunu publishes AI-generated probability forecasts on world events, markets, and policy. Forecasts update as new signals come in and are graded correct/incorrect at close — full track record at brunu.ai/forecasts. Informational only. Not financial, legal, or medical advice.